Patient characteristics and immunologic markers
| . | Case 1 . | Case 2 . | Case 3 . | Case 4 . | Case 5 . | Case 6 . | Case 7 . | Case 8 . | Case 9 . | Case 10 . |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | 52 | 58 | 51 | 50 | 55 | 46 | 65 | 56 | 59 | 75 |
| Sex | Male | Male | Male | Female | Male | Male | Female | Female | Female | Female |
| Past history | Two individual early gastric cancers at the ages of 48 and 51 y | NP | Advanced gastric cancer at the age of 47 y | NP | NP | NP | NP | Advanced gastric cancer at the age of 52 | NP | NP |
| H pylori | − | + | + | + | + | + | + | + | + | + |
| Original pathologic diagnosis | NK/T-cell lymphoma | NK/T-cell lymphoma | Gastritis with histiocytosis. NK/T-cell lymphoma* | Adenocarcinoma | Lymphoma, s/o LyGa* | NK/T-cell lymphoma; NK/T-cell lymphoma* | T-cell lymphoma | T-cell lymphoma; NK/T-cell lymphoma* | Lymphoma, s/o LyGa, s/o LyGa* | T-cell lymphoma |
| Follow-up examinations, days from the initial biopsy | 45, 73, 276, 577, 1165 | 55, 239, 442, 675, 896, 1121, 1497 | 336,† 365, 484, 701, 1065, 1429, 1793 | 41,‡ 167, 1360 | 13,† 132 | 50,† 56‡ | 38, 81, 137, 207, 361, 515, 742, 1029, 1281, 1515 | 98, 154, 236,† 256, 333, 452, 585, 790 | 113,† 232† | 30, 59, 143, 232, 354 |
| Patient status | Well at 145 mo | Well at 50 mo | Well at 60 mo | Well at 46 mo | Well at 33 mo | Well at 60 mo | Well at 56 mo | Well at 29 mo | Well at 18 mo | Well at 12 mo |
| Treatment | Observation | Observation | Observation | Subtotal gastrectomy | Observation | Total gastrectomy | Observation | Observation | Observation | Observation |
| CD2 | − | +w | +w | +w | − | + | +w | − | + | + |
| CD3 | + | + | + | + | + | + | + | + | + | + |
| CD4 | ND | − | − | − | − | − | − | − | − | − |
| CD5 | − | − | − | − | − | − | − | − | − | − |
| CD7 | + | + | + | + | + | + | + | + | + | + |
| CD8 | ND | − | − | ND | − | − | − | − | − | − |
| CD20 | − | − | − | − | − | − | − | − | − | − |
| CD56 | + | + | + | + | + | + | + | + | + | + |
| Cytotoxic molecules | TIA1+ | TIA1+, granzyme B+, perforin+ | TIA1+, granzyme B+, perforin+ | TIA1+, granzyme B+, perforin+ | Granzyme B+ | TIA1+, Perforin+ | Perforin+ | TIA1+ | Granzyme B+ | Granzyme B+ |
| EBER | − | − | − | − | − | − | − | − | − | − |
| Other markers | CD16−, betaF1− | CD16−, CD30−, CD45+w, CD57−, CD68−, CD123−, betaF1−, ALK−, MPO−, MIB1 index 10% | CD16−, CD30−, CD45+w, CD57−, CD68−, CD123−, betaF1−, ALK−, TdT−, MIB1 index 30% | CD16−, CD45+, CD68−, CD123−, betaF1−, CD43+ | TCRαβ−, TCRγδ−, CD161−, TCRVα24−, CD16−, CD158a− | CD10−, CD21−, BCL2+, CD45RO+, CD68−, MIB1 index 20% | MIB1 index 20%, CD21− |
| . | Case 1 . | Case 2 . | Case 3 . | Case 4 . | Case 5 . | Case 6 . | Case 7 . | Case 8 . | Case 9 . | Case 10 . |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | 52 | 58 | 51 | 50 | 55 | 46 | 65 | 56 | 59 | 75 |
| Sex | Male | Male | Male | Female | Male | Male | Female | Female | Female | Female |
| Past history | Two individual early gastric cancers at the ages of 48 and 51 y | NP | Advanced gastric cancer at the age of 47 y | NP | NP | NP | NP | Advanced gastric cancer at the age of 52 | NP | NP |
| H pylori | − | + | + | + | + | + | + | + | + | + |
| Original pathologic diagnosis | NK/T-cell lymphoma | NK/T-cell lymphoma | Gastritis with histiocytosis. NK/T-cell lymphoma* | Adenocarcinoma | Lymphoma, s/o LyGa* | NK/T-cell lymphoma; NK/T-cell lymphoma* | T-cell lymphoma | T-cell lymphoma; NK/T-cell lymphoma* | Lymphoma, s/o LyGa, s/o LyGa* | T-cell lymphoma |
| Follow-up examinations, days from the initial biopsy | 45, 73, 276, 577, 1165 | 55, 239, 442, 675, 896, 1121, 1497 | 336,† 365, 484, 701, 1065, 1429, 1793 | 41,‡ 167, 1360 | 13,† 132 | 50,† 56‡ | 38, 81, 137, 207, 361, 515, 742, 1029, 1281, 1515 | 98, 154, 236,† 256, 333, 452, 585, 790 | 113,† 232† | 30, 59, 143, 232, 354 |
| Patient status | Well at 145 mo | Well at 50 mo | Well at 60 mo | Well at 46 mo | Well at 33 mo | Well at 60 mo | Well at 56 mo | Well at 29 mo | Well at 18 mo | Well at 12 mo |
| Treatment | Observation | Observation | Observation | Subtotal gastrectomy | Observation | Total gastrectomy | Observation | Observation | Observation | Observation |
| CD2 | − | +w | +w | +w | − | + | +w | − | + | + |
| CD3 | + | + | + | + | + | + | + | + | + | + |
| CD4 | ND | − | − | − | − | − | − | − | − | − |
| CD5 | − | − | − | − | − | − | − | − | − | − |
| CD7 | + | + | + | + | + | + | + | + | + | + |
| CD8 | ND | − | − | ND | − | − | − | − | − | − |
| CD20 | − | − | − | − | − | − | − | − | − | − |
| CD56 | + | + | + | + | + | + | + | + | + | + |
| Cytotoxic molecules | TIA1+ | TIA1+, granzyme B+, perforin+ | TIA1+, granzyme B+, perforin+ | TIA1+, granzyme B+, perforin+ | Granzyme B+ | TIA1+, Perforin+ | Perforin+ | TIA1+ | Granzyme B+ | Granzyme B+ |
| EBER | − | − | − | − | − | − | − | − | − | − |
| Other markers | CD16−, betaF1− | CD16−, CD30−, CD45+w, CD57−, CD68−, CD123−, betaF1−, ALK−, MPO−, MIB1 index 10% | CD16−, CD30−, CD45+w, CD57−, CD68−, CD123−, betaF1−, ALK−, TdT−, MIB1 index 30% | CD16−, CD45+, CD68−, CD123−, betaF1−, CD43+ | TCRαβ−, TCRγδ−, CD161−, TCRVα24−, CD16−, CD158a− | CD10−, CD21−, BCL2+, CD45RO+, CD68−, MIB1 index 20% | MIB1 index 20%, CD21− |
NP indicates nothing in particular; s/o, suspected of; ND, not done; and +w, weakly positive.
In case 3, 5, 6, 8 and 9, multiple biopsies showed the presence of LyGa.
LyGa is present on follow-up examination.
In follow-up examinations, days of gastrectomy or gastroscopy with or without biopsy from the initial biopsy are described.